DFA
ESPR

DHJJ Financial Advisors’s Esperion Therapeutics ESPR Stock Holding History

DHJJ Financial Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,430
Closed -$25.8K – 1089
2026
Q1 		$25.8K Hold
9,430
– – 0.01% 497
2025
Q4 		$34.9K Hold
9,430
– – 0.01% 433
2025
Q3 		$25K Buy
9,430
+6,380
+209% +$12.3K 0.01% 461
2025
Q2 		$3K Hold
3,050
– – ﹤0.01% 652
2025
Q1 		$4.39K Hold
3,050
– – ﹤0.01% 581
2024
Q4 		$6.71K Hold
3,050
– – ﹤0.01% 533
2024
Q3 		$5.03K Buy
3,050
+550
+22% +$1.11K ﹤0.01% 545
2024
Q2 		$5.55K Hold
2,500
– – ﹤0.01% 502
2024
Q1 		$6.7K Buy
2,500
+1,000
+67% +$2.43K ﹤0.01% 481
2023
Q4 		$4.49K Hold
1,500
– – ﹤0.01% 497
2023
Q3 		$1.47K Buy
+1,500
New +$2.17K ﹤0.01% 563

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

DHJJ Financial Advisors's ESPR Position: Q2 2026 in Review

DHJJ Financial Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 9,430 shares — an estimated $25.8K sold.

DHJJ Financial Advisors first reported a position in ESPR in Q3 2023 and held it in 11 quarters. The position peaked at $34.9K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • DHJJ Financial Advisors reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • DHJJ Financial Advisors sold 9,430 Esperion Therapeutics shares in Q2 2026, an estimated $25.8K.
  • DHJJ Financial Advisors first reported a position in Esperion Therapeutics in Q3 2023 and held it in 11 quarters.
  • DHJJ Financial Advisors's Esperion Therapeutics position peaked at $34.9K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on DHJJ Financial Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.